

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June US\$ millions	(Unaudited)	
	2022	2021
Profit before Taxation		
From continuing operations	761.6	547.6
From a discontinued operation	-	86.4
Adjustments for:		
Finance costs	229.2	243.3
Depreciation	164.5	175.1
Amortization of other intangible assets	71.2	71.2
Write-down of inventories to net realizable value	28.4	7.3
Provision for impairment losses	16.1	39.9
Loss on changes in fair value of biological assets	7.4	2.4
Employee share-based compensation benefit expenses	0.9	1.0
Share of profits less losses of associated companies and joint ventures	(164.9)	(170.4)
Gains on step acquisition of a joint venture	(65.7)	-
Interest income	(25.1)	(19.9)
Gain on disposal of an associated company	(2.5)	(22.2)
Gain on deconsolidation of a discontinued operation	-	(66.6)
Reversal of provision for onerous contracts, net	-	(4.4)
Gain on disposal of property, plant and equipment, net	-	(0.6)
Others	(2.3)	(1.1)
	1,018.8	889.0
(Increase)/decrease in working capital	(154.7)	77.0
Net cash generated from operations	864.1	966.0
Interest received	22.2	18.9
Interest paid	(213.4)	(223.0)
Taxes paid	(230.6)	(213.1)
Net Cash Flows From Operating Activities	442.3	548.8
Dividends received from associated companies	149.3	131.8
Disposal of financial assets at fair value through other comprehensive income	30.1	-
Decrease in short-term deposits with original maturity of more than three months	19.1	2.0
Dividends received from financial assets at fair value through other comprehensive income	14.1	10.7
Cash acquired from step acquisition of a joint venture	9.0	-
Dividend received from a joint venture	8.8	-
Disposal of an associated company	2.5	148.4
Disposal of property, plant and equipment	2.1	1.1
Payment for retention amount payable	(650.0)	-
Investments in other intangible assets	(380.9)	(355.0)
Payments for purchase of property, plant and equipment	(88.1)	(212.8)
(Increase)/decrease in restricted cash	(50.8)	24.0
Investment in financial assets at fair value through profit or loss	(20.0)	-
Investments in biological assets	(8.6)	(5.1)
Increased investments in joint ventures	(6.6)	(0.4)
Advances to joint ventures	(5.2)	(15.4)
Increased investments in associated companies	(4.0)	(2.0)
Purchases of investment properties	(1.0)	-
Investment in an associated company	(1.0)	-
Advances to an associated company	(0.6)	-
Investment in a joint venture	-	(147.5)
Acquisition of financial assets at fair value through other comprehensive income	-	(105.1)
Instalment payment for acquisition of a subsidiary company	-	(50.7)
Deconsolidation of a discontinued operation	-	126.9
Net Cash Flows Used in Investing Activities	(981.8)	(449.1)